Portfolio Lab

BIO-TECHNE Corp

  • Stock
  • Ticker TECH
  • ISIN US09073M1045
  • Nasdaq

Health care · Biotechnology · USA

$72.67 −0.04%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of BIO-TECHNE Corp since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

TECHGlobal equities (VT)

$10,000 grew to $29,444. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −67.2% in 05/2026, measured from the peak in 09/2021. The old peak has not been reached again yet.

1-year return
+24.4%
5-year return p.a.
−9.9%
10-year return p.a.
+11.4%
Volatility p.a.
33.3%
Largest decline
−67.2%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue297316317287296311321300
Gross profit194215199188191208211197
Operating income4739-244854757437
EBITDA75663.372791009860
Net income3523-183838515528
Earnings per share0.220.14-0.110.240.240.320.350.18
Balance sheet
Total assets2,6702,6442,5582,5262,5232,5512,5872,637
Liabilities592626639560512465479471
Equity2,0782,0181,9191,9662,0112,0852,1082,166
Cash178141162145173210265350
Cash flow
Operating cash flow8441982882879573
Capital expenditure-6.8-10-4.9-5.4-5.9-9.1-8.5-5.9
Free cash flow7831932276788767

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2021 at +63.4%, weakest 2022 at −35.7%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
6 Nov 2026$0.18
24 Aug 2026$0.35
6 May 2026$0.32
4 Feb 2026$0.24
5 Nov 2025$0.24
22 Aug 2025−$0.11
8 May 2025$0.14
6 Feb 2025$0.22
5 Nov 2024$0.21
22 Aug 2024$0.26
6 May 2024$0.31
7 Feb 2024$0.17

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€10bn
Market cap in trading currency
$11.4bn
Enterprise value
$11.3bn
P/E
66.7
P/S
9.29
P/B
5.27
EV/Sales
9.17
EV/EBITDA
33.4
Earnings yield
1.5%
FCF yield
2.7%

Results (last four quarters)

Revenue
$1.23bn
Gross profit
$808m
EBITDA
$338m
Net income
$172m
Earnings per share
$1.09
Revenue per share
$7.82
Revenue growth
+4.6%
Earnings growth
−25.9%

Profitability

Gross margin
65.8%
Operating margin
19.6%
Net margin
14.0%
Return on equity
8.3%
Return on assets
6.5%

Balance sheet and cash flow

Cash
$350m
Cash per share
$2.23
Financial debt
$200m
Debt/equity %
9
Current ratio
2.28
Book value per share
$13.79
Operating cash flow
$338m
Free cash flow
$308m

Dividend

Dividend yield
0.55%
Dividend (12 months)
$0.40
Yield (12 months)
0.55%
Payout ratio
37%
Ex-dividend date
13 Nov 2026

Shares and trading

Shares outstanding
157m
Volume
3.65m
Avg. volume 3 months
2.83m
Relative volume
1.3

Price and technicals

Price
$72.67
1 day
0.0%
52-week high
$72.84
52-week low
$43.30
Distance to 52-week high
−0.2%
Distance to 52-week low
+67.8%
Distance to 50-day line
+0.1%
Distance to 200-day line
+14.3%
RSI (14)
50
Volatility 1M
1.7%

Performance

1 week
−0.2%
1 month
+0.1%
3 months
+0.4%
6 months
+50.7%
YTD
+23.6%
1 year
+25.7%

Dates

Fiscal year end
30 Jun 2026
Most recent quarter
30 Sep 2026

Frequently asked questions

How has TECH performed since 11/2016?

$10,000 grew to $29,444 by 20 Nov 2026, which is +11.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is TECH?

Volatility was 33.3% per year, measured on monthly returns. The largest decline from a peak was −67.2%, with the low in 05/2026.

How does TECH compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, TECH returned +11.4% at 33.3%. The correlation of monthly returns was 0.55; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

BIO-TECHNE Corp (TECH): Return and risk | Portfolio Lab